Tarja Ikonen

Orion Corporation (Finland) — Finland

Medicine · Health Sciences

24h-index2.5kcitations65works3.52yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Prostate Cancer Treatment and Research(25), Hormonal and reproductive studies(11), Estrogen and related hormone effects(10), Genetic factors in colorectal cancer(9), Sexual Differentiation and Disorders(7)

Publications65 total

1605P Opevesostat (MK-5684/ODM-208), an oral CYP11A1 inhibitor, in metastatic castration-resistant prostate cancer (mCRPC): Updated CYPIDES phase II results
Annals of Oncology·2024· 3 citedOpen Access
ODM-209, a CYP 11A1 inhibitor in patients with mCRPC: Results from the STESIDES phase 1 study.
Journal of Clinical Oncology·2024· 1 cited
Prevalence and Spectrum of <i>AR</i> Ligand-Binding Domain Mutations Detected in Circulating-Tumor DNA Across Disease States in Men With Metastatic Castration-Resistant Prostate Cancer
JCO Precision Oncology·2024· 6 citedOpen Access
MK-5684 (ODM-208), a CYP11A1 inhibitor, in patients with metastatic castration-resistant prostate cancer (mCRPC) with and without AR-LBD mutations: CYPIDES phase 2 results.
Journal of Clinical Oncology·2024· 4 cited
Targeted Inhibition of CYP11A1 in Castration-Resistant Prostate Cancer
NEJM Evidence·2023· 22 citedOpen Access
Supplementary Table S1 and Figures S1-S7 from ODM-203, a Selective Inhibitor of FGFR and VEGFR, Shows Strong Antitumor Activity, and Induces Antitumor Immunity
2023Open Access
Data from ODM-203, a Selective Inhibitor of FGFR and VEGFR, Shows Strong Antitumor Activity, and Induces Antitumor Immunity
2023Open Access
Supplementary Table S1 and Figures S1-S7 from ODM-203, a Selective Inhibitor of FGFR and VEGFR, Shows Strong Antitumor Activity, and Induces Antitumor Immunity
2023Open Access
Data from ODM-203, a Selective Inhibitor of FGFR and VEGFR, Shows Strong Antitumor Activity, and Induces Antitumor Immunity
2023Open Access
Real-world assessment of AR-LBD mutations in metastatic castration-resistant prostate cancer.
Journal of Clinical Oncology·2023· 9 cited
1420P The pharmacokinetics and the pharmacodynamic effect of ODM-208, an inhibitor of cholesterol side-chain cleavage enzyme (CYP11A1)
Annals of Oncology·2022Open Access
1364MO Preliminary phase II results of the CYPIDES study of ODM-208 in metastatic castration-resistant prostate (mCRPC) cancer patients
Annals of Oncology·2022· 2 citedOpen Access
Impact of activating androgen receptor (AR) mutations on AR sensitivity to alternative ligands and response to ODM-208, a selective, first-in-class CYP11A1 inhibitor, in patients with advanced metastatic castration-resistant prostate cancer (mCRPC).
Journal of Clinical Oncology·2022· 5 cited
Phase 1 results of the ODM-208 first-in-human phase 1-2 trial in patients with metastatic castration-resistant prostate cancer (CYPIDES).
Journal of Clinical Oncology·2022· 9 cited
Abstract 1753: Targeting cancer with selective cbp/p300 bromodomain inhibitors
Cancer Research·2020· 2 cited
Phase I/IIa, open-label, multicentre study to evaluate the optimal dosing and safety of ODM-203 in patients with advanced or metastatic solid tumours
ESMO Open·2020· 8 citedOpen Access
ODM-203, a Selective Inhibitor of FGFR and VEGFR, Shows Strong Antitumor Activity, and Induces Antitumor Immunity
Molecular Cancer Therapeutics·2018· 33 citedOpen Access
Phase I/II study of ODM-203, a selective dual FGFR/VEGFR inhibitor, in patients with advanced solid tumours
Annals of Oncology·2018· 4 citedOpen Access
a selective matriptase inhibitor blocks tumor growth and metastasis while displaying potent antiangiogenic activity in an orthotopic murine renal cell cancer model
Journal of Oncology Research and Therapy·2018
Abstract 118: Targeting cancer with a novel BET bromodomain inhibitor ODM-207
Cancer Research·2017· 1 cited
page 1 of 4Next →

Frequent Co-authors

Johanna Schleutker(21), Teuvo L.J. Tammela(20), Mika Matikainen(14), Ville Autio(12), Chris Garratt(11), Pasi A. Koivisto(10), Pekka Kallio(9), Karim Fizazi(9), Jorma J. Palvimo(8), Olli A. Jänne(8), Nina Mononen(8), Joan E. Bailey‐Wilson(7), Olli Kallioniemi(7), Pasi Pohjanjousi(7), Annika Rökman(6), Henna Fredriksson(6), Alice Bernard‐Tessier(6), Natalie Cook(6), Eija H. Seppälä(5), Anu‐Maarit Moilanen(5)